Object. Experience with whole-brain radiation therapy for metastatic tumors in the brain has identified a subset of tumors that exhibit decreased local control with fractionated regimens and are thus termed radioresistant. With the advent of frameless radiosurgery, fractionated radiosurgery (2-5 fractions) is being used increasingly for metastatic tumors deemed too large or too close to crucial structures to be treated in a single session. The authors retrospectively reviewed metastatic brain tumors treated at 2 centers to analyze the dependency of local control rates on tumor radiobiology and dose fractionation.
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H istorical experience with whole-brain radiation therapy (WBRT) has shown that certain tumor types respond poorly to fractionated radiotherapy. 4, 7, 9, [25] [26] [27] These tumor types include melanoma, renal cell carcinoma, and sarcoma. Stereotactic radiosurgery is an increasingly common method for treating all types of brain metastases. [5] [6] [7] 26 One of the advantages of radiosurgery is the ability to deliver large amounts of highly conformal radiation in a single dose, and radiosurgery has been widely used as both monotherapy and as an adjuvant boost for the treatment of intracranial metastatic disease. Classic radioresistance (to fractionated therapy) is not a known predictor of response to radiosurgery. 1, 12 For the treatment of larger metastatic lesions, it is increasingly common to fractionate the radiosurgical dose to minimize toxicity. It is unknown whether this fractionated radiosurgery would be equally effective in both classically radiosensitive and radioresistant tumors (analogous to single-fraction radiosurgery) or display less efficacy in radioresistant tumors (analogous to fractionated radiotherapy such as WBRT). We retrospectively reviewed patients treated with stereotactic radiosurgery at 2 centers (The University of North Carolina at Chapel Hill and Georgetown University) and compared the results obtained using short fractionated radiosurgical plans (2-5 fractions) with those obtained using single-fraction radiosurgery in relation to local control rates.
Methods

Participants and Study Design
Institutional review board approval for the accumulation of clinical data for this study was obtained from both The University of North Carolina at Chapel Hill and Georgetown University Hospital. Records of 257 patients treated with radiosurgery for intracranial metastases at both institutions from 2006 to 2011 were reviewed. Forty-three patients who received pretreatment WBRT were excluded to yield a final set of 214 patients. These 214 patients had newly diagnosed brain metastases, biopsyconfirmed primary or metastatic disease, and no prior treatment with intracranial radiation. The patients were divided into one group of 30 patients with radioresistant tumors and another group of 184 patients with radiosensitive tumors. The median follow-up was 10 months (IQR 3.8-14.2 months). Metastatic tumors from renal cell carcinoma, melanoma, or sarcoma were classified as being radioresistant; all other tumors were classified as radiosensitive. This retrospective data set was subsequently analyzed to attempt to detect a divergence in outcomes for radioresistant tumors compared with radiosensitive tumors treated with either single-fraction or fractionated radiosurgery. A direct comparison of single-fraction radiosurgery to multifraction radiosurgery within each histological group, radiosensitive or radioresistant, was not performed because of the variance in the biologically equivalent dose between fractionated and single-fraction radiosurgery. Rather, we compared radioresistant control rates with radiosensitive control rates within treatment groups using either single-fraction or multifraction radiosurgery.
Radiosurgical Treatment
Both institutions used the CyberKnife Robotic Radiosurgery System (Accuray). Patients were generally considered favorable for radiosurgery if they had 1-3 intracerebral metastases of 3 cm or smaller and a favorable performance status. In addition, patients with larger tumors or more numerous metastases were considered eligible for radiosurgery for the alleviation of neurological symptoms or as part of a comprehensive treatment plan. Final decisions to treat were made by a team including both a radiation oncologist and a neurosurgeon. The final fractionation and dosage determinations were made after consideration of the gross tumor volume and adjacent critical structures, such as the brainstem and optic chiasm, with larger tumor volumes and tumors adjacent to critical structures receiving smaller doses or fractionated radiation. Radiosurgery was delivered in frameless fashion according to the treatment plan created. If the radiosurgery failed, the patient could receive further treatment including resection or WBRT at the discretion of the treating physicians.
Outcomes Assessment
Outcomes were assessed using serial MRI obtained as a part of routine clinical follow-up. In patients who could not be observed with MRI, CT imaging was performed. Patients underwent imaging every 2-3 months postradiosurgery at the discretion of the treating radiation oncologist and neurosurgeon. For patients with multiple intracranial lesions at the time of radiosurgery, or for those who developed new lesions distal to the site of treatment, local control was evaluated for the lesions initially treated with radiosurgery. Radiosurgery was considered to have failed locally if there were signs of radiographic progression at the radiosurgical treatment site. Overall survival (OS) and local control were calculated from the last day of radiosurgical treatment until the date of death or local failure. All patients were monitored clinically for radiosurgery-associated toxicity throughout the length of follow-up, and all such toxicities were recorded and scored using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.
Statistical Analysis
Fractionation status was categorized as single fraction or fractionated for the purpose of analysis, and patients were classified as either having radioresistant or radiosensitive tumors per the previous discussion. Differences in pretreatment variable distribution between radioresistant and radiosensitive groups were assessed using the Mann-Whitney test or chi-square test for continuous and categorical variables, respectively. We used univariate Cox proportional-hazards regression to determine the association of pretreatment and treatment-related variables, including fractionation status, on the time to local failure and reported results using odd ratios (OR) and p values. The results of univariate analysis were subsequently confirmed using a multivariable proportional hazards model to measure their combined effect on local control. Kaplan-Meier survival curves were constructed to graphically depict survival and local control, and the log-rank test was used to determine differences in time to death or local control. All ranges are reported as interquartile range (IQR), which is a more robust measure of dispersion than simple range. All data management and analyses were conducted using SAS (version 9.2, SAS Institute, Inc.) and SPSS (version 20.0, IBM, Inc.).
Results
Patient and Treatment Characteristics
The median patient age was 61.8 years (IQR 53.5-68.7 years); 101 patients were male and 113 patients were female (Table 1) . There were more women in the radiosensitive tumor group (p = 0.021), including 42 women with breast cancer. The median number of intracerebral metastases at the time of treatment was 2 for the radioresistant group and 1 for the radiosensitive group (p = 0.041). The median tumor diameter in the radioresistant group was 2.1 cm (IQR 1.0-2.5 cm), while the median tumor diameter in the radiosensitive group was 1.4 cm (IQR 0.8-2.1 cm), and this difference was significant (p = 0.036). When stratified by fractionation, however, for the single-fraction group the median diameter of treated lesions was 1.1 cm (IQR 0.8-2.1 cm) for the radioresistant tumors, and 1 cm (IQR 0.7-1.5 cm) for the radiosensitive tumors (p = 0.265). For the fractionated group, the median tumor diameter of treated lesions was 2.5 cm (IQR 1.9-3.4 cm) for the radioresistant group, and 2.1 cm (IQR 1.4-2.8 cm) for the radiosensitive group (p = 0.169). For a more thorough analysis, tumor volume was also considered. Radioresistant tumors treated with fractionated radiosurgery had a median volume of 65.5 cm 3 (IQR 28.7-158.7 cm Tumors occurred in a wide range of intracranial locations, both supratentorial and infratentorial. The median dose delivered to the radiosensitive lesions and radioresistant lesions was 20 Gy ( Table 2 ). The median isodose for treated lesions was 81% (IQR 78%-83%). Forty-three (20%) of the 214 patients had salvage therapy, with 17 patients undergoing salvage surgery and 26 patients receiving WBRT.
Local Control Results
Patients with radioresistant and radiosensitive tumor histology receiving single-fraction radiosurgery had equivalent rates of local control (Fig. 1 upper) . The median time to local failure after single-fraction radiosurgery in the radiosensitive group was 30.9 months and was not yet reached at 35 months in the radioresistant group (p = 0.46). On univariate analysis, local control for patients receiving single-fraction radiosurgery was associated with tumor diameter (OR 1.32, p = 0.05) and trended toward an association with radiation dose (p = 0.06), but was not associated with radiobiological classification (p = 0.67) ( Table 3) . In contrast, patients receiving fractionated radiosurgery for radioresistant tumors had worse local tumor control than patients with radiosensitive tumors (p = 0.001 [ Fig. 1 lower] ). The median local control for radioresistant tumors was 14.4 months (95% CI 6.1-22.7 months), and for the radiosensitive tumors it was 41.5 months (95% CI 20.3-62.8 months) (p = 0.001). On univariate analysis, local control in patients receiving fractionated radiosurgery was strongly predicted by radiobiological classification with an OR of 6.6 (p = 0.004) ( Table 3) .
Multivariable proportional hazards models were constructed to validate these results in both the singlefraction and fractionated groups. Both models included the following as factors: radiation dose, tumor diameter, and radiobiological classification. For tumors receiving fractionated radiosurgery, radiobiology independently predicted local control (OR 5.37, p = 0.03) ( Table 4) . For tumors treated with a single fraction, no variables were independently predictive of local control.
Overall Survival
The median OS for all patients was 10 months (95% CI 6.9-13.1 months). Patients with radioresistant tumors had a median survival of 6.4 months (95% CI 5.8-7 months) while patients with radiosensitive tumors had a median survival of 11.6 months (95% CI 8.2-15.0 months) (Fig. 2) . This difference in survival between patients with radioresistant and radiosensitive tumors was not significant (p = 0.084).
Toxicity
Of 168 patients with data on late toxicity, 4 patients 
Discussion
This retrospective, 2-center study of radiation-naive brain metastases reports that radioresistant brain metastases treated with fractionated radiosurgery have a diminished local control rate compared with radiosensitive tumor types treated with fractionated radiosurgery. On the other hand, control rates for radioresistant brain metastases and radiosensitive tumor types are equivalent for tumors treated with single-fraction radiosurgery. These findings are analogous to the results for WBRT, where radioresistant metastases are less responsive to fractionated treatment. 5, 8, 16, 24 Despite being a retrospective study with the potential for a large degree of bias, the study has controlled for potential bias with statistics and an open presentation of data. The findings, although somewhat expected given historical experience with WBRT and weakened by the study's retrospective nature, are provocative and ought to motivate subsequent exploration in a rigorous prospective manner.
These results are particularly relevant in light of 2 recent studies suggesting that cancer-related deaths and symptomatic progression in patients with brain metastases are associated with locally progressive intracerebral disease. 5, 18 With the expanding use of radiosurgery for brain metastases and a trend toward applying it to larger lesions by fractionating the dose, this is also a timely observation. Several other studies have examined the tumor subtype of brain metastases as a predictor of local control in the case of single-fraction radiosurgery and have reported conflicting results, but this is the first study that has specifically analyzed the effect of fractionation on the response of various tumor types to radiosurgery.
1,10,12
We believe that the different responses of specific tumor types to different fractionation regimens are due to intrinsic, tumor-specific radiobiological mechanisms, which require further elucidation. 25 In both univariate and multivariate analyses, only tumor radiobiology, and not tumor size or dose, was associated with local control in the fractionated group. Interestingly, we see a trend toward improved local control for radioresistant brain metastases in the case of single-fraction radiosurgery. Although not significant in the present study, this does reflect an observation originally reported by Flickinger and colleagues almost 2 decades ago. 10 Increasingly, radiosurgery is being incorporated into the management of metastatic brain disease with or without WBRT. 2, 13 Until recently, many studies have treated all brain metastases equally in their analysis of both prognosis and treatment efficacy. Our understanding of metastatic brain disease, driven by evidence-based medicine and advances in genomics, is lending evidence to the belief that brain metastases ought to be considered with regard to their primary site of origin. 11, 16, 21, 23 This study * Similar to the univariate analysis, radiobiology classification was highly associated with control in the group of tumors receiving fractionated radiosurgery, but not in tumors receiving single-fraction radiosurgery.
Fig. 2.
Kaplan-Meier plots of OS for all patients (upper) and patients with radiosensitive versus radioresistant brain metastases (lower). The patients with radiosensitive tumors have a superior OS likely due to the favorable outcomes of the patients with brain metastases from breast cancer.
bolsters the evidence that not all metastatic brain tumors behave equally, and it is particularly novel in that it shows a difference in response to a specific radiation therapy parameter (fractionation) rather than a simple difference in prognosis.
These findings pose a challenging clinical scenario for large tumors from radioresistant primary tumors. The desire to fractionate to reduce toxicity to normal brain structures must be carefully weighed against the increased likelihood of failure. Certainly, these results could be used to advocate for the use of resection either to completely resect these lesions or to debulk radioresistant tumors to facilitate single-fraction radiosurgery. Conversely, for metastatic brain tumors of a radiosensitive subtype, fractionation may prove to be a more successful strategy, affording both a good local control with a reduced risk of the debilitating late toxicity that can occur with high-dose intracranial radiation. In this case, higher radiosurgical doses provided through a fractionated treatment plan could prove to be a useful, noninvasive therapy. With regard to the decision to fractionate for tumors bordering on critical structures or eloquent cortex, these results are encouraging for fractionated therapy for radiosensitive tumor types due to the excellent local control even with fractionated treatment. To spare critical or eloquent areas from toxicity, for radiosensitive tumor types, fractionated radiosurgery ought to be encouraged because of its diminished toxicity to normal tissue. 15 For the purposes of this study, the direct comparison of outcomes between patients receiving single-fraction versus fractionated radiosurgery was avoided. Primarily, this was because patients were selected to receive either single-fraction or fractionated radiosurgery based on important tumor characteristics. In general, small lesions away from key normal structures were treated with single fractions, making this a better prognosis group. Since radiosensitivity was not a variable used to make the selection for single-fraction or fractionated radiotherapy, the impact of radiosensitivity within the single-fraction group and the fractionated group can be assessed. The comparison between single-fraction and fractionated treatment was avoided because of the radiobiological consequence of fractionation as well. Fractionation of radiation doses has a significant impact on the biologically effective dose delivered with therapy. While it is possible to theoretically model the biologically effective dose using the linear-quadratic and multihit, as well as other, equations, these models remain theoretical and not fully validated, particularly for the high dosages used in radiosurgical treatment. Therefore, current methods do not allow meaningful direct comparison between singlefraction and fractionated treatment groups without risk of confounding results due to differences in biologically effective doses between the two strategies.
Overall survival was notably different between the radiosensitive and radioresistant subtypes, with markedly decreased survival in the radioresistant group. This is not unexpected due to the underlying systemic diseases in this group (melanoma, sarcoma, and renal cell carcinoma) carrying a worse prognosis than the tumor types in the radiosensitive group (especially breast cancer). Variation in systemic therapies, status of extracranial disease, and performance status could also potentially explain this discrepancy. Additionally, toxicity overall was relatively mild owing to the generally low toxicity of radiosurgical interventions. 2 There are several limitations to this study. Most significantly, this was a retrospective study and it suffers from the shortcomings of all retrospective studies. Most significantly, assignment to treatment groups was not random and was based on the assumptions of the treating team as to which strategy was more likely to be successful. While the question of bias is somewhat mitigated by the multiinstitutional nature of the study, it is still an inherent weakness of hypothesis-driven retrospective studies. With regard to variation in tumor size, while the tumors treated with fractionated radiotherapy were generally larger, they were not significantly different between histological subtypes (radioresistant and radiosensitive). Most importantly, tumor size was not a significant factor in predicting response in either of the multivariable models, while tumor subtype was overwhelmingly significant in the case of radiosensitive tumors. Another possible source of bias is that 20% of patients received salvage therapy such as WBRT or surgery, although no patient received prior intracranial radiation. Most had been censored prior to this due to local progression, but additional local therapy, while meeting the standard of care, could have impacted local control rates. Fortunately, the number of patients affected appears small. In addition, we would have expected the radiosensitive group to have received a boost in local control if the salvage WBRT were a powerful influence. However, as seen in the Kaplan-Meier analysis, the radiation-sensitive group trended to worse local control, albeit not to a significant degree. As such, we do not think the salvage therapy of the patient confounds the fundamental finding of the study. Last, optimal dosing for fractionated radiosurgery is largely unknown, and it is conceivable that an increased fractionated dose may be able to achieve equivalent local control for both radioresistant and radiosensitive tumors.
With regard to follow-up, minor variations existed between follow-up observation, with the median followup being 10 months (IQR 3.8-14.2 months). While ideally follow-up would be longer to better assess the incidence of local recurrence, in the context of metastatic disease, prolonged follow-up is often difficult to obtain. However, for the purposes of ascertaining local control rates in the context of diffusely metastatic disease for a variety of tumor types, this follow-up length is reasonable, with other studies reporting a variety of median times to recurrence ranging from 7 months to a little over 1 year. 14, 22 There also exists some controversy as to the heterogeneity of radiobiology within tumor types, particularly in melanoma. 3, 19, 20 Many of these studies are done in cultured cell lines that lack a comparable microenvironment to that of brain metastases and generally do not have the full biological complexity of in vivo tumors. This latter point has been demonstrated by several studies that have shown metastases as generally having increased radioresistance compared with their primary tumors from which many cultured lines are derived. 17, 20 It is therefore reason-able in the present study to classify renal cell carcinoma, melanoma, and sarcoma metastases as being radioresistant tumors in light of the current clinical and scientific evidence pertaining to their radiobiology, and by virtue of the fact that they are metastases.
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Conclusions
This retrospective, 2-center study demonstrates a difference in local control with fractionated stereotactic radiosurgery for metastatic brain tumors of radioresistant subtype compared with radiosensitive tumors, but equivalent local control with high-dose single-fraction radiosurgery. These results suggest that not all brain metastases respond equally to fractionated radiosurgery, but that they do so in a manner consistent with past experience using WBRT. For radioresistant brain metastases, which appear to respond less favorably than radiosensitive brain metastases, the results suggest a need for either increased fractionated dose or the use of surgical techniques to facilitate singlefraction radiosurgery. For radiosensitive tumors, however, fractionation appears to be a safe and effective option when a single-fraction approach is deemed unsafe.
